AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9779697 — intervention group
Group type: COMPARATOR
Intervention: Usual breakthrough medication
Number of subjects: 62
Study 7843102 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure to Cd and Ni
Number of subjects: 12
Study 7843102 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure to Cd and Ni
Number of subjects: 12
Study 7843102 — intervention group
Group type: COMPARATOR
Intervention: Light exposure to Cd (< 100 micrograms/m3)
Number of subjects: 12
Study 7843102 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exposure to Cd (> 200 micrograms/m3)
Number of subjects: 12
Study 7843102 — intervention group
Group type: COMPARATOR
Intervention: Light exposure to Ni (< 100 micrograms/m3)
Number of subjects: 12
Study 7843102 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exposure to Ni (> 200 micrograms/m3)
Number of subjects: 12
Study 3339482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education program for internal medicine residents
Number of subjects: 45
Study 31325350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits (eating rice at least three times per week or eating fish at least once per week)
Number of subjects: 323
Study 31325350 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent infections
Number of subjects: 323
Study 31325350 — intervention group
Group type: COMPARATOR
Intervention: Control group (partners of patients with CIDP)
Number of subjects: 323
Study 27334234 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% rebate on targeted fruits and vegetables (TFVs) purchased with SNAP benefits
Number of subjects: 7500
Study 27334234 — intervention group
Group type: COMPARATOR
Intervention: Usual SNAP benefits
Number of subjects: 7500
Study 25644275 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Stat (collagen and thrombin mixture)
Number of subjects: 164
Study 25644275 — intervention group
Group type: COMPARATOR
Intervention: Vacuum drainage
Number of subjects: 164
Study 25644275 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Stat
Number of subjects: 164
Study 23241989 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV‐Hib‐HepB plus PCV7
Number of subjects: 0
Study 23241989 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Number of subjects: 0
Study 23241989 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV/Hib plus HepB plus PCV7
Number of subjects: 0
Study 23241989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21098340 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multitask exercise program performed to the rhythm of piano music
Number of subjects: 134
Study 21098340 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group (scheduled to start the program 6 months later)
Number of subjects: 134
Study 17483245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin E levels in tumours with an infiltrative growth pattern (n = 141)
Number of subjects: 187
Study 17483245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin E levels in tumours with a pushing margin phenotype
Number of subjects: 187
Study 17483245 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment
Number of subjects: 187
Study 17038140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction (AVJ) ablation followed by biventricular pacing
Number of subjects: 180
Study 17038140 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic rate control
Number of subjects: 180
Study 12868995 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab plus early low-dose cyclosporin
Number of subjects: 100
Study 12868995 — intervention group
Group type: COMPARATOR
Intervention: OKT3 induction therapy
Number of subjects: 100
Study 10720881 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day for 8 weeks)
Number of subjects: 0
Study 10720881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9188207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline
Number of subjects: 12
Study 9188207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1447432 — intervention group
Group type: EXPERIMENTAL
Intervention: clomipramine
Number of subjects: 66
Study 1447432 — intervention group
Group type: EXPERIMENTAL
Intervention: lofepramine
Number of subjects: 66
Study 1447432 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 66
Study 4078175 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency increments
Number of subjects: 32
Study 4078175 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency decrements
Number of subjects: 32
Study 4078175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity increments
Number of subjects: 32
Study 4078175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity decrements
Number of subjects: 32
Study 31630589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, fentanyl, and propofol
Number of subjects: 114
Study 31630589 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and propofol
Number of subjects: 114
Study 29068321 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma group (atopic and non-atopic)
Number of subjects: 314
Study 29068321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthma group
Number of subjects: 314
Study 29068321 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-atopic asthma group
Number of subjects: 314
Study 29068321 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without asthma)
Number of subjects: 314
Study 26686695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in women
Number of subjects: 332
Study 26686695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in men
Number of subjects: 332
Study 26686695 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DM) in women
Number of subjects: 332
Study 26686695 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DM) in men
Number of subjects: 332
Study 24239513 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT Girls obesity prevention program
Number of subjects: 330
Study 24239513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 330
Study 22199136 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) with good adherence (≥ 4h/night)
Number of subjects: 85
Study 22199136 — intervention group
Group type: COMPARATOR
Intervention: Adaptive servo-ventilation (ASV) with poor adherence (<4h/night)
Number of subjects: 85
Study 20182403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVT) of 4 mg triamcinolone acetonide
Number of subjects: 24
Study 20182403 — intervention group
Group type: COMPARATOR
Intervention: Subtenon infusion (STI) of 40 mg triamcinolone acetonide
Number of subjects: 24
Study 17492909 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric advance directives (PADs)
Number of subjects: 28
Study 16264062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 400 mug once daily in the evening
Number of subjects: 268
Study 16264062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 mug twice daily
Number of subjects: 268
Study 16264062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 12131245 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 43
Study 12131245 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-pain patients
Number of subjects: 43
Study 10223933 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 209763 (10 mg/kg)
Number of subjects: 43
Study 10223933 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 209763 (various doses: 0.25, 1.25, 5.0, or 10.0 mg/kg)
Number of subjects: 43
Study 10223933 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 209763 (1.25 to 10.0 mg/kg)
Number of subjects: 43
Study 10223933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10223933 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 209763
Number of subjects: 43
Study 7829790 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 395
Study 7829790 — intervention group
Group type: COMPARATOR
Intervention: primary angioplasty
Number of subjects: 395
Study 2398130 — intervention group
Group type: EXPERIMENTAL
Intervention: Coe-pak
Number of subjects: 226
Study 2398130 — intervention group
Group type: EXPERIMENTAL
Intervention: Wondrpak
Number of subjects: 226
Study 2398130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobetec
Number of subjects: 226
Study 25384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid prophylaxis (hourly titration to keep gastric pH above 3.5)
Number of subjects: 100
Study 25384 — intervention group
Group type: COMPARATOR
Intervention: No specific form of prophylaxis (control group)
Number of subjects: 100
Study 25384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid medication (for those who bled in control group)
Number of subjects: 100
Study 30760846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray (0.5 mL of 5% phenylephrine)
Number of subjects: 12
Study 30760846 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 12
Study 28289193 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate treatment
Number of subjects: 959
Study 28289193 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate treatment in patients with kelch13 mutant parasites
Number of subjects: 959
Study 28289193 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally acquired immunity
Number of subjects: 959
Study 26343840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics for 7 days plus standard stroke unit care
Number of subjects: 1217
Study 26343840 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke unit care only (control)
Number of subjects: 1217
Study 22415440 — intervention group
Group type: EXPERIMENTAL
Intervention: Retro-rectus placement of non-crosslinked porcine acellular dermal matrix (Strattice™)
Number of subjects: 49
Study 22415440 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal placement of non-crosslinked porcine acellular dermal matrix (Strattice™)
Number of subjects: 49
Study 22415440 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (retro-rectus and intraperitoneal)
Number of subjects: 49
Study 20934696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Binder(®)
Number of subjects: 80
Study 20934696 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM‐Sling(®)
Number of subjects: 80
Study 20934696 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐POD(®)
Number of subjects: 80
Study 20934696 — intervention group
Group type: COMPARATOR
Intervention: Transfer to hospital bed
Number of subjects: 80
Study 19270033 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg daily for 7 days followed by 200 mg daily for 7 days)
Number of subjects: 20
Study 16706692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation once a day for 5 days (acute gout arthritis)
Number of subjects: 104
Study 16706692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation once a day for 21 days (chronic pyrophosphate arthropathy)
Number of subjects: 104
Study 16706692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation once a day for 21 days (chronic hydroxyapatite arthropathy)
Number of subjects: 104
Study 16706692 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg orally, twice a day for 5 days (acute gout arthritis)
Number of subjects: 104
Study 16706692 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg orally, twice a day for 21 days (chronic pyrophosphate arthropathy)
Number of subjects: 104
Study 16706692 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg orally, twice a day for 21 days (chronic hydroxyapatite arthropathy)
Number of subjects: 104
Study 15066943 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 15066943 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone (Control)
Number of subjects: 0
Study 11103185 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6‐8 mg kg‐1 h‐1
Number of subjects: 30
Study 11103185 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 0.8‐1.0% end tidal
Number of subjects: 30
Study 9340238 — intervention group
Group type: EXPERIMENTAL
Intervention: Showering postoperatively (water contact)
Number of subjects: 121
Study 9340238 — intervention group
Group type: COMPARATOR
Intervention: Keeping the incision dry (control group)
Number of subjects: 121
Study 8114054 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intensive instruction by PN teams
Number of subjects: 52
Study 8114054 — intervention group
Group type: COMPARATOR
Intervention: Direct group instructions by PP teams
Number of subjects: 52
Study 3534317 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine (10 mg, orally twice daily for 3 days)
Number of subjects: 160
Study 3534317 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (2 mg, orally twice daily for 3 days)
Number of subjects: 160
Study 3534317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally twice daily for 3 days)
Number of subjects: 160
Study 3076867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline eye ointment, twice daily for five days each month for six months
Number of subjects: 368
Study 3076867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline, 5 mg/kg body weight weekly for three weeks
Number of subjects: 368
Study 3076867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulphametopyrazine, 35 mg/kg body weight weekly for three weeks
Number of subjects: 368
Study 31408773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 92
Study 31408773 — intervention group
Group type: COMPARATOR
Intervention: Relaxation practice (active control)
Number of subjects: 92
Study 28590084 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% discount on fruits and vegetables
Number of subjects: 0
Study 25952979 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 100
Study 25952979 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessments
Number of subjects: 100
Study 25952979 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive function (NCF) assessments
Number of subjects: 100
Study 25952979 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy quality
Number of subjects: 100
Study 25952979 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 100
Study 23237736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaporized cannabis (1.29%)
Number of subjects: 39
Study 23237736 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose vaporized cannabis (3.53%)
Number of subjects: 39
Study 23237736 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 39
Study 22142435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-4-Fun program (8-week multi-component school-based health-related fitness education intervention)
Number of subjects: 128
Study 19737492 — intervention group
Group type: EXPERIMENTAL
Intervention: Drank before attending the bar
Number of subjects: 666
Study 19737492 — intervention group
Group type: EXPERIMENTAL
Intervention: Drank only at the bar
Number of subjects: 666
Study 16391587 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 microg/day (5,000 IU) of vitamin D(2)
Number of subjects: 38
Study 16391587 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg/day (10,000 IU) of vitamin D(2)
Number of subjects: 38
Study 16391587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D(2))
Number of subjects: 38
Study 16391587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D(2) groups (125 and 250 microg/day) combined
Number of subjects: 38
Study 15311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A masking functions with small spacings and large eccentricities
Number of subjects: 0
Study 15311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B masking with letter-like nonletter flankers
Number of subjects: 0
Study 15311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interletter spacing and eccentricity with increasing SOA
Number of subjects: 0
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows' milk formula (1789 infants)
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk (1859 infants)
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (1737 infants)
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed (824 infants)
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding during the first 8 weeks combined with infrequent exposure to small amounts of CM
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum from mothers of infants with IgE-mediated CMA
Number of subjects: 6209
Study 11065065 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta1 in colostrum
Number of subjects: 6209
Study 9316509 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (1,000 mg/day)
Number of subjects: 101
Study 9316509 — intervention group
Group type: COMPARATOR
Intervention: Control (no lipid-lowering therapy)
Number of subjects: 101
Study 8403306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (loading dose, 40 mg 1 hour before PTCA; maintenance dose, 40 mg bid for 6 months)
Number of subjects: 658
Study 8403306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 8403306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 658
Study 8403306 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 658
Study 3094627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (active drug)
Number of subjects: 81
Study 3094627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29673395 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Number of subjects: 1200
Study 29673395 — intervention group
Group type: COMPARATOR
Intervention: 6-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Number of subjects: 1200
Study 28606567 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellmune 250 mg/d
Number of subjects: 100
Study 28606567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26520140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal intervention involving scaling, root-planing, and removal of non-salvageable teeth, conducted over three visits (baseline, 3-month, and 6-month follow-up).
Number of subjects: 600
Study 26520140 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group receiving periodontal treatment 24 months after baseline.
Number of subjects: 600
Study 23735703 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PRE)
Number of subjects: 528
Study 23735703 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (PERI)
Number of subjects: 528
Study 20958278 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 100
Study 20958278 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 100
Study 18842740 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm touch enhancement intervention
Number of subjects: 68
Study 18842740 — intervention group
Group type: COMPARATOR
Intervention: Behavior monitoring control group
Number of subjects: 68
Study 16567126 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dose 154 mg)
Number of subjects: 556
Study 16567126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 16567126 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dose 158 mg)
Number of subjects: 556
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 60 microg/kg
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 microg/kg
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: No cytokine treatment
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 microg/kg (balanced for risk factors)
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (balanced for risk factors)
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (without risk factors)
Number of subjects: 50
Study 14565651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (without risk factors)
Number of subjects: 50
Study 14565651 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of febrile neutropenia
Number of subjects: 50
Study 10425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella pneumoniae glycoproteins extract (1 g/day for one week a month for three months)
Number of subjects: 42
Study 10425883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7498216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 62
Study 7498216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 62
Study 7498216 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 62
Study 2197428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoglucid (0.565 gm, solution of 1%) weekly for 6 weeks, then monthly for 1 year
Number of subjects: 0
Study 2197428 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole‐limpet hemocyanin (1 mg intracutaneously, then 30 mg bladder instillations weekly for 6 weeks, then monthly for 1 year)
Number of subjects: 0